Suppr超能文献

环状RNA在肾细胞癌耐药中的分子机制

Molecular mechanism of circRNAs in drug resistance in renal cell carcinoma.

作者信息

Qin Shuang, Wang Yuting, Wang Peijun, Lv Qi

机构信息

Department of Medical Imaging, Tongji Hospital, Tongji University School of Medicine, Xincun Road No. 389, Shanghai, 200065, China.

出版信息

Cancer Cell Int. 2022 Nov 24;22(1):369. doi: 10.1186/s12935-022-02790-w.

Abstract

Renal cell carcinoma (RCC) is one of the most common malignant tumors with a poor response to radiotherapy and chemotherapy. The advent of molecular targeted drugs has initiated great breakthroughs in the treatment of RCC. However, drug resistance to targeted drugs has become an urgent problem. Various studies across the decades have confirmed the involvement of circular RNAs (circRNAs) in multiple pathophysiological processes and its abnormal expression in many malignant tumors. This review speculated that circRNAs can provide a new solution to drug resistance in RCC and perhaps be used as essential markers for the early diagnosis and prognosis of RCC. Through the analysis and discussion of relevant recent research, this review explored the relationship of circRNAs to and their regulatory mechanisms in drug resistance in RCC. The results indicate an association between the expression of circRNAs and the development of RCC, as well as the involvement of circRNAs in drug resistance in RCC.

摘要

肾细胞癌(RCC)是最常见的恶性肿瘤之一,对放疗和化疗反应不佳。分子靶向药物的出现开创了RCC治疗的重大突破。然而,对靶向药物的耐药性已成为一个紧迫的问题。数十年来的各种研究证实,环状RNA(circRNA)参与多种病理生理过程,且在许多恶性肿瘤中表达异常。本综述推测,circRNA可为RCC的耐药性提供新的解决方案,或许还可作为RCC早期诊断和预后的重要标志物。通过对近期相关研究的分析和讨论,本综述探讨了circRNA与RCC耐药性的关系及其调控机制。结果表明,circRNA的表达与RCC的发生发展相关,且circRNA参与了RCC的耐药过程。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0920/9686082/366dd671da2a/12935_2022_2790_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验